APOE and Alzheimer disease: Because APOE4 carriers had greater estimates of change in MMSE score over time than did all subjects (Table 2), our power analyses show that, if only APOE4 carriers were enrolled, 168 AD subjects per group or 147 AD subjects per group would be necessary for clinical trials of imipramine or olanzapine, respectively.